Health News Roundup: Hantavirus Outbreak on Cruise Ship and Drug Advancements

Recent health news highlights include a hantavirus outbreak on a luxury cruise ship, promising pancreatic cancer drug trials, and significant investments in pharmaceutical manufacturing. Researchers report high occurrence of mostly low-grade side effects in a trial for Revolution Medicines' pancreatic cancer drug. Meanwhile, a hantavirus outbreak on a cruise ship sees health officials on alert while the ship heads towards the Canary Islands. Eli Lilly announces investments in Indiana to boost drug production, and Novo Nordisk shows strong sales in the U.S. Lilly's weight-loss products also see promising developments.

An experimental drug from Revolution Medicines has shown promising trial results, nearly doubling survival time for pancreatic cancer patients despite some manageable side effects, according to researchers on Wednesday. The trial, a first for the drug daraxonrasib, offers new hope in evolving standard care for metastatic pancreatic cancer.

Argentina's health ministry is set to test rodents in Ushuaia following a deadly hantavirus outbreak traced to a cruise ship. Officials continue to track movements of affected Dutch travelers, as the CDC monitors U.S. passengers amidst this concerning development reported by WHO.

CVS Health revised its profit forecasts upward after effective medical cost control measures, reporting heightened first-quarter earnings. Meanwhile, Eli Lilly plans to invest an additional $4.5 billion in Indiana to support production of new weight-loss medications, marking significant expansion efforts in recent years.